Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control
about
MiRNAs and Other Epigenetic Changes as Biomarkers in Triple Negative Breast CancerIntegrating genetics and epigenetics in breast cancer: biological insights, experimental, computational methods and therapeutic potentialmicroRNA: Diagnostic PerspectiveBayesian clinical classification from high-dimensional data: Signatures versus variability.miRpower: a web-tool to validate survival-associated miRNAs utilizing expression data from 2178 breast cancer patients.MicroRNA profile in very young women with breast cancerDysregulation of microRNAs in breast cancer and their potential role as prognostic and predictive biomarkers in patient management.MicroRNA gene polymorphisms and environmental factors increase patient susceptibility to hepatocellular carcinoma.Critical analysis of the potential for microRNA biomarkers in breast cancer management.Analysis of miRNA expression profiles in breast cancer using biclustering.The ErbB4 CYT2 variant protects EGFR from ligand-induced degradation to enhance cancer cell motility.Mouse mammary stem cells express prognostic markers for triple-negative breast cancerComparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers.Genomic Complexity Profiling Reveals That HORMAD1 Overexpression Contributes to Homologous Recombination Deficiency in Triple-Negative Breast Cancers.Differentially Expressed miRNAs in Hepatocellular Carcinoma Target Genes in the Genetic Information Processing and Metabolism PathwaysmiR-34a Silences c-SRC to Attenuate Tumor Growth in Triple-Negative Breast Cancer.Noncoding RNAs in breast cancer.A novel double-negative feedback loop between miR-489 and the HER2-SHP2-MAPK signaling axis regulates breast cancer cell proliferation and tumor growthmiR-564 acts as a dual inhibitor of PI3K and MAPK signaling networks and inhibits proliferation and invasion in breast cancer.Splicing imbalances in basal-like breast cancer underpin perturbation of cell surface and oncogenic pathways and are associated with patients' survivalFunctional and prognostic significance of the genomic amplification of frizzled 6 (FZD6) in breast cancerIntegrated MicroRNA-mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer.Differentially expressed miRNAs in triple negative breast cancer between African-American and non-Hispanic white women.microRNAs: a new class of breast cancer biomarkers.Molecular markers for breast cancer diagnosis, prognosis and targeted therapy.PIM1 kinase regulates cell death, tumor growth and chemotherapy response in triple-negative breast cancer.Breast cancer stem cells programs: enter the (non)-code.RNA Bioinformatics for Precision Medicine.ADAM9 enhances CDCP1 by inhibiting miR-1 through EGFR signaling activation in lung cancer metastasis.Targeted exome sequencing of Korean triple-negative breast cancer reveals homozygous deletions associated with poor prognosis of adjuvant chemotherapy-treated patientsmiR-105/93-3p promotes chemoresistance and circulating miR-105/93-3p acts as a diagnostic biomarker for triple negative breast cancer.Differential microRNA expression in breast cancer with different onset age.MicroRNA-409-5p is upregulated in breast cancer and its downregulation inhibits cancer development through downstream target of RSU1.Integrated genomics and functional validation identifies malignant cell specific dependencies in triple negative breast cancer.Angiogenic role of miR-20a in breast cancer.Cancer epigenetics: Moving forward.Therapeutic vulnerability of multiple myeloma to MIR17PTi, a first-in-class inhibitor of pri-miR-17-92
P2860
Q26775086-0D928E5C-2C54-4D6B-8D3F-D952B2E56C83Q26782613-9B68A8DB-9302-4B1A-9161-B5C43A9D78A5Q26797259-31CD1A71-7F02-450F-B3F1-C155EBD19FD5Q31059415-B8B07C64-5F9D-41A8-8647-2B86EB57793DQ31136911-37F7367A-0D9D-4E16-AA6E-2DD986A7FDE7Q34468715-161A9EE2-EF6F-4B95-96D3-218801B50969Q35094742-31314B33-11CA-4E02-B026-F70F6C2427C9Q35108392-5DBD04A2-6326-4300-AA18-8A12D9652850Q35137273-F3C1DBA2-B010-42BE-ADAB-6261BC26C2B5Q35141171-05B15A70-C10F-443E-AB79-06163E17FF10Q35228445-3D1A511D-BC51-4FB8-B304-0438B619813CQ35238287-61E6AFD5-E6D5-4C32-96B4-330784724557Q35685370-43D18EC3-CB07-4613-8156-FA6019AC522BQ35812762-1D7917BB-C833-4ACC-A65E-648A56986D68Q36512091-3AFD6335-9276-46CC-B1C7-4632EC7D5FFAQ36586444-B3CFF0DF-204C-4DE8-A911-A8B2880F8703Q36935047-E18054CE-4AA5-4475-B252-E0A411477086Q37109741-392B3FF4-035E-430A-AB4B-5AAAD43A1C2FQ37236236-929CC3CC-1E57-4B24-A2F2-06719729BF59Q37563571-357F5E45-0477-4B26-8FDA-642EB1D7BD0FQ37595930-B65040FD-AA08-474C-8C84-0C607715A0CBQ37631676-D58D7148-7D94-4BD7-B381-57652F68FA99Q37694781-9D71D6AF-8EA7-48E3-92E2-FF77368A13F0Q38197675-823DF45A-2BF3-48CD-AAB4-22475A7BACDDQ38236904-0FA9440C-093F-49C4-967D-7CA4EED1A797Q38735131-8BCD5850-95AA-467D-BEAE-EF30B33727AFQ38765793-909CFB5B-A61A-42DF-9AF1-6E220ED37B3CQ39222032-5930EE27-0695-4ACD-A1B3-D5ABDCBC6C3AQ41471073-2751FFE5-19CE-4154-AD38-797A5FAEA2BFQ41899534-1FEE2250-2232-405D-9140-37777E9C5D12Q47152122-6705715C-252C-4B8C-8D49-F3CE63CBE34DQ48259419-1EAE0D24-25F0-4E95-AE6E-6BFB2754A415Q50687509-03DD8754-CA1E-49FA-8195-E4C301F6FE87Q52726773-A6675182-828A-4FCF-B439-A2F4F10B941AQ53698485-B14A839E-F5CE-4985-87BC-0DD3CD602DD6Q55177661-7D97CD0C-DD2B-448C-97CE-978D2C67A6C0Q58761702-1455B9B0-5EC5-4702-8500-E1C45AE8B669
P2860
Integrated genomic analysis of triple-negative breast cancers reveals novel microRNAs associated with clinical and molecular phenotypes and sheds light on the pathways they control
description
2013 nî lūn-bûn
@nan
2013 թուականի Սեպտեմբերին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի սեպտեմբերին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
Integrated genomic analysis of ...... t on the pathways they control
@ast
Integrated genomic analysis of ...... t on the pathways they control
@en
type
label
Integrated genomic analysis of ...... t on the pathways they control
@ast
Integrated genomic analysis of ...... t on the pathways they control
@en
prefLabel
Integrated genomic analysis of ...... t on the pathways they control
@ast
Integrated genomic analysis of ...... t on the pathways they control
@en
P2093
P2860
P50
P356
P1433
P1476
Integrated genomic analysis of ...... t on the pathways they control
@en
P2093
Brian Burford
Emanuele de Rinaldis
Grazyna M Fedorowicz
Patrycja Gazinska
P2860
P2888
P356
10.1186/1471-2164-14-643
P407
P50
P577
2013-09-23T00:00:00Z
P5875
P6179
1033823909